We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

CERTEST BIOTEC

Certest Biotec, S.L. develops and manufactures IVD products in the human clinical testing field, including rapid test... read more Featured Products: More products

Download Mobile App




CerTest to Run ‘More than Diagnostics’ Campaign Throughout 2023

By LabMedica International staff writers
Posted on 01 Feb 2023
Print article
Image: The ‘More than Diagnostics’ campaign expresses the company’s ambition to continue growing and advancing towards an exciting future (Photo courtesy of CerTest)
Image: The ‘More than Diagnostics’ campaign expresses the company’s ambition to continue growing and advancing towards an exciting future (Photo courtesy of CerTest)

The world is currently experiencing a change of era. Even as it still emerging from the SARS-CoV-2 pandemic, there are new unexpected challenges that must be met. For CerTest Biotec (Zaragoza, Spain), the recent years of the pandemic have been a turning point that have made it a better company in every sense. CerTest has demonstrated that under extreme conditions, it has the ability to work towards achieving a common goal, offer a befitting response to the extraordinary circumstances and, instill confidence among its customers, suppliers and partners.

CerTest has now announced that the company will run its campaign ‘More than Diagnostics’ throughout 2023 in acknowledgement of the transformation that it has gone through, accelerated by the COVID-19 pandemic. CerTest’s ‘More than Diagnostics’ campaign expresses the company’s ambition to continue growing and advancing towards an exciting future, with people’s health remaining its key focus.

CerTest remains optimistic about the future and is well aware of the need to sustain its efforts and to continue backing the four concepts which have defined the company right from the start - service, responsibility, confidence and research. Over the coming period, CerTest plans to employ more people, build more facilities, increase its R&D activities, and come up with more products and solutions that are better as well as more effective.

Related Links:
CerTest Biotec 

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Malaria Test
STANDARD Q Malaria P.f/Pan Ag
New
Mumps Virus Test
ZEUS ELISA Mumps IgG Test System

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.